权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

2/2 Collaborative Study: Testosterone Augmentation in Women

2/2 合作研究：女性睾酮水平增强

基本信息

批准号：
8875769
负责人：
LINDA L CARPENTER
金额：
$ 21.11万
依托单位：
BUTLER HOSPITAL (PROVIDENCE, RI)
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-24 至 2016-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8875769
关键词：
Academic Medical Centers Address Adverse effects Affect Androgens Antidepressive Agents Area Arousal Collaborations Data Data Analyses Depressed mood Disease remission Dose Endocrinology Fatigue Female Future Glycols Health Hormones Hospitals Intervention Intervention Studies Joints Libido Major Depressive Disorder Mental Depression Multicenter Trials Patients Pharmaceutical Preparations Physiological Physiological Processes Placebos Population Postmenopause Psychiatrist Psychiatry Public Health Quality of life Randomized Controlled Trials Recording of previous events Recruitment Activity Research Research Domain Criteria Research Personnel Residual state Resistance Sample Size Sampling Selective Serotonin Reuptake Inhibitor Serotonin Uptake Inhibitors Severities Sex Functioning Sexual Dysfunction Site Study Subject Symptoms Testing Testosterone Therapeutic Validation Woman base career data management depressive symptoms double-blind placebo controlled trial drug candidate effective therapy efficacy testing experience hormone therapy improved interest multidisciplinary novel open label patient oriented research randomized placebo controlled trial response suicidal risk treatment-resistant depression

项目摘要

DESCRIPTION (provided by applicant): Major depressive disorder is a significant public health problem, disproportionately affecting women. Approximately 70% of patients do not respond or only partially respond to standard SSRI treatment despite adequate dosing. In our open-label pilot data, two-thirds of women with major depressive disorder who were resistant or partially resistant to antidepressants achieved a response to very low-dose, physiologic transdermal testosterone administration; one-third of women treated achieved remission after 8 weeks of therapy, with no hyperandrogenic side effects. We propose a collaborative, randomized, placebo-controlled trial to determine whether larger, multi-center trials are indicated to investigate whether low-dose testosterone is an efficacious and well-tolerated augmentation strategy in women with major depressive disorder and SSRI partial/nonresponse. We propose a collaborative, multidisciplinary study from two academic medical centers in order to increase sample size, accelerate recruitment and increase sample diversity.

描述(由申请人提供)：严重抑郁障碍是一个严重的公共卫生问题，对女性的影响不成比例。大约70%的患者对标准的SSRI治疗没有反应或只有部分反应，尽管剂量足够。在我们的开放标签试验数据中，三分之二对抗抑郁药物耐药或部分耐药的患有严重抑郁障碍的女性对极低剂量的生理性经皮睾酮治疗有反应；三分之一的接受治疗的女性在治疗8周后获得缓解，没有高雄激素副作用。我们建议进行一项协作性、随机性、安慰剂对照试验，以确定是否需要更大规模的多中心试验。目的：研究小剂量睾酮对患有严重抑郁障碍和SSRI部分/无反应的女性是否有效和耐受性良好的强化治疗策略。我们建议从两个学术医学中心进行一项合作的、多学科的研究，以增加样本量，加速招募，并增加样本多样性。